Antitumor and immunomodulatory activity of resveratrol on experimentally implanted tumor of H22 in Balb/c mice

Table 1 Effect of resveratrol on cytotoxicity of peritoneal macrophages (MΦ) against H22 cells in vitro (n = 3)

Resveratrol(mg•l-1)	Cytotoxicity of MΦ: H22 (10:1)	Φ(%) MΦ: H22 (25:1)
Control	12.6 ± 7.9	15.6 ± 6.0
1.25	10.9 ± 2.9a	10.6 ± 5.4a
2.50	12.5 ± 3.2a	16.4 ± 1.8a
5.0	13.4 ± 2.8a	27.6 ± 2.6a
10.0	14.6 ± 3.7a	18.3 ± 4.2a
20.0	16.7 ± 4.7b	20.2 ± 3.1b

^aP > 0.05,

^bP < 0.05 vs control.

Table 2 Inhibitory rates of resveratrol on H22 in mice in vivo

Group	Dose mg•kg-1	Route	Mice begin/end	Tumor weight(¯x ± s) (g)	Inhibitory rate (%)	P value
Control		ip	10/9b	1.81 ± 0.62
Resveratrol 1	500	ip	10/8b	1.24 ± 0.40	31.5	< 0.05a
Resveratrol 2	1000	ip	10/9b	0.99 ± 0.35	45.6	< 0.05a
Resveratrol 3	1500	ip	10/10	0.93 ± 0.25	48.7	< 0.05a

^aP < 0.05 vs control;

^bkilled by other mice.

Table 3 Effects of resveratrol on serum antibody IgG, plaque forming cells (PFC) in Balb/c mice with implanted tumor of H22 in vivo

Group	Dose mg•kg-1	Route	IgG/g•l-1	PFC/106 cells
Normal mice	NS	ip	278	441 ± 32
Control	NS	ip	196a	297 ± 57a
Resveratrol 1	500	ip	208a	305 ± 53a
Resveratrol 2	1000	ip	236a	328 ± 49a
Resveratrol 3	1500	ip	245a	348 ± 46a

^aP > 0.05 vs normal mice or control.

Table 4 Effect of resveratrol on TNF-α production induced by LPS in Balb/c mice

Group	Dose (mg•kg-1)	Route	TNF-α activity specific lysis
Normal mice	NS	ip	7.1 ± 3.2
Control	NS	ip	16.3 ± 2.3a
Resveratrol 1	500	ip	15.8 ± 2.0ab
Resveratrol 2	1000	ip	17.7 ± 2.9ab
Resveratrol 3	1500	ip	19.5 ± 3.1ab
Control+BCG	200	ip	29.8 ± 3.7ab

^aP < 0.05 vs normal mice;

^bP > 0.05 vs control.